194 related articles for article (PubMed ID: 18204353)
1. Duloxetine-induced cutaneous adverse reaction.
Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
[No Abstract] [Full Text] [Related]
2. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
3. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
4. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
5. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
6. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Ravindran LN; Eisfeld BS; Kennedy SH
J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
[No Abstract] [Full Text] [Related]
7. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao MC; Liu CY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
[No Abstract] [Full Text] [Related]
8. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
Ashton AK; Longdon MC
Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668
[No Abstract] [Full Text] [Related]
9. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
10. [Duloxetine (Yentreve) in the general practice test: recommendation by the experts. Effective and tolerable therapy of symptoms in female stress incontinence].
Krankenpfl J; 2005; 43(7-10):189-90. PubMed ID: 16515261
[No Abstract] [Full Text] [Related]
11. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine: a dual reuptake inhibitor.
Dugan SE; Fuller MA
Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
14. Bleeding gums: duloxetine may be the cause.
Balhara Y; Sagar R; Varghese ST
J Postgrad Med; 2007; 53(1):44-5. PubMed ID: 17244971
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
Lai CH
J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662
[No Abstract] [Full Text] [Related]
18. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
Maund E; Tendal B; Hróbjartsson A; Lundh A; Gøtzsche PC
BMJ; 2014 Jun; 348():g3555. PubMed ID: 24899651
[TBL] [Abstract][Full Text] [Related]
19. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
Maund E; Tendal B; Hróbjartsson A; Jørgensen KJ; Lundh A; Schroll J; Gøtzsche PC
BMJ; 2014 Jun; 348():g3510. PubMed ID: 24899650
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine treatment of social anxiety disorder with comorbid major depression.
Lin CC
J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
